Poor
Not Aligned
Patient Risk:
Moderate
Summary
The response contains several claims about eye inflammation/uveitis and management that are not supported by the provided COSENTYX prescribing-information excerpts. The label excerpts provided focus on infections/TB/IBD/hypersensitivity and do not substantiate the eye-specific claims; therefore multiple key statements are unsupported, lowering alignment.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is an IL-17A inhibitor.
Supported by provided label excerpt that describes secukinumab as an IL-17 inhibitor (e.g., Warnings: 'IL-17 inhibitors including COSENTYX' in 5.1; and ingredient: secukinumab (IL-17A antagonist) referenced in prompt's label/verification section).
Unsupported Statements
Cosentyx is used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis.
The provided excerpts do not include the FDA-approved Indications section; therefore the indication claims cannot be verified from the supplied label text.
Eye problems are a known concern with the drug class IL-17A inhibitors.
The provided label excerpts include no eye-specific warnings/precautions for IL-17 inhibitors or COSENTYX.
Eye problems are a known concern with the underlying inflammatory conditions that Cosentyx treats.
The provided label excerpts do not discuss baseline eye-inflammation risk in the treated diseases.
Reported eye-related side effects of Cosentyx include inflammation of the eye.
The provided label excerpts list many postmarketing infections/hypersensitivity/skin reactions but do not mention eye inflammation as an adverse reaction.
Uveitis (inflammation inside the eye) has been linked to Cosentyx.
No uveitis/uveal inflammation is mentioned in the provided label excerpts.
Uveitis can cause eye pain, light sensitivity, redness, and blurry vision.
No symptom constellation for uveitis/eye inflammation appears in the provided label excerpts.
New eye inflammation while on Cosentyx warrants urgent medical assessment.
No eye-specific counseling/urgency language is present in the provided label excerpts.
If symptoms suggestive of uveitis or other inflammatory eye conditions develop after starting Cosentyx, clinicians treat that as a warning sign.
No eye-specific warning-sign guidance is present in the provided label excerpts.
Psoriatic disease and spondyloarthritis (conditions treated by Cosentyx) are associated with a higher baseline risk of eye inflammation, including uveitis.
No baseline risk information for eye inflammation/uveitis in these diseases is included in the provided label excerpts.
Management of eye inflammation typically involves contacting the prescriber promptly.
The provided label excerpts only include general infection/TB/hypersensitivity counseling; they do not provide eye-inflammation management counseling.
Management of eye inflammation typically involves eye specialist evaluation (often ophthalmology).
No eye specialist/ophthalmology recommendation appears in the provided label excerpts.
Management of eye inflammation may involve deciding to hold or discontinue Cosentyx depending on diagnosis and severity.
The provided label excerpts include discontinuation guidance for serious hypersensitivity reactions and for serious infections until resolved, but do not mention holding/discontinuing for eye inflammation/uveitis.
Management of eye inflammation typically involves starting the right eye treatment for the inflammation.
No eye-specific treatment recommendations (e.g., concomitant ocular therapies) are included in the provided label excerpts.
Contradictions
Important Omissions
Key on-label safety monitoring and interruption/discontinuation language for infections (including serious opportunistic/fatal infections), TB evaluation/avoid active TB, and IBD monitoring/exacerbation risk.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because the response includes multiple unsupported eye-uveitis claims and management instructions not present in the provided label excerpts, it could mislead clinicians/patients about label-supported risks and appropriate actions. The label excerpts provided do contain major safety warnings (infections/TB/IBD/hypersensitivity), but they were not incorporated into the eye-focused claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Eye/uveitis claims and management guidance are not supported by the provided COSENTYX FDA label excerpts; indication claims also cannot be verified from the supplied text.
Suggested Improvement
Remove or rewrite eye/uveitis-specific statements unless the corresponding FDA label sections (e.g., warnings/precautions, adverse reactions, patient counseling, or adverse event descriptions) are provided and directly support them. For label fidelity, restrict claims to those explicitly present in the supplied prescribing-information excerpts (e.g., infections/TB/IBD/hypersensitivity) and cite the relevant sections.